Treatment of CD20 Antibody Plus CIK for Patients With Refractory Lymphomas
NCT01828008
·
clinicaltrials.gov ↗
UNKNOWN
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Lymphomas
Sponsor
Han weidong